Medical Devices Latin America

Latin America Polygenic Risk Scores Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Latin America Polygenic Risk Scores Market Industry Trends and Forecast to 2034: Segmented by (Condition, User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Latin America · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $8.9 Mn Placeholder estimate
Estimate 2025 $10.6 Mn 5.1% of the global market
Projected 2034 $49.9 Mn 371.4% Adds $39.3 Mn over 9 forecast years
CAGR 2025–2034 18.8% Faster than 93% of 180 Medical Devices markets here
Key players 5
  • Latin America is 5.07% of the global market.
  • Among regions, the largest is North America at $95.6 Mn.
  • Fastest growing: APAC at 19.2% a year.
  • Latin America ranks 4th of 6 by size among regions.

Market size projection

Latin America

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$39.3 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Polygenic Risk Scores Market market size by year, Latin America
YearMarket sizeChange that yearSince 2025
2024 (estimate) $8.9 Mn — —
2025 (base) $10.6 Mn +$1.7 Mn —
2026 (forecast) $12.6 Mn +$2.0 Mn +18.8%
2027 (forecast) $14.9 Mn +$2.4 Mn +41.1%
2028 (forecast) $17.7 Mn +$2.8 Mn +67.7%
2029 (forecast) $21.1 Mn +$3.3 Mn +99.2%
2030 (forecast) $25.0 Mn +$4.0 Mn +136.6%
2031 (forecast) $29.8 Mn +$4.7 Mn +181.1%
2032 (forecast) $35.4 Mn +$5.6 Mn +234%
2033 (forecast) $42.0 Mn +$6.6 Mn +296.8%
2034 (forecast) $49.9 Mn +$7.9 Mn +371.4%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Latin America Polygenic Risk Scores Market Analysis at a glance
Market size, 2025$10.6 Mn placeholder estimate
Forecast, 2034$49.9 Mn placeholder estimate
Growth (CAGR), 2025–203418.8% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsCondition and user (see all)
Key playersGenomics plc, Allelica, Myriad Genetics, Inc., 23andMe, Color Health (see all)
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Latin America Polygenic Risk Scores Market Analysis Executive Summary

Polygenic risk scores combine many small genetic effects to estimate a person's risk of common diseases such as heart disease and diabetes.

Key segments of the polygenic Risk Scores market include condition (Cardiovascular Disease, Cancer and Diabetes) and user (Clinicians, Consumers and Researchers).

Bar chart: Latin America Polygenic Risk Scores market size, 2024–2034, placeholder estimates. $8.9 Mn in 2024, $10.6 Mn in 2025 and $49.9 Mn in 2034, 18.8% CAGR.
Latin America Polygenic Risk Scores market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Latin America Polygenic Risk Scores Market Dynamics

Market Growth Drivers

The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the polygenic Risk Scores market.

Opportunity

Routine use of genomics in screening, pharmacy and primary care gives the polygenic Risk Scores market large room to grow.

Market Restraints

Data privacy concerns, limited reimbursement for some tests, shortages of genetic counsellors and complex data analysis hold back the polygenic Risk Scores market.

Competitive Landscape for Polygenic Risk Scores Market in Latin America

The polygenic Risk Scores market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Polygenic Risk Scores Market in Latin America

Polygenic Risk Scores in Latin America: rules and payment

In some of the countries we cover here, medical devices are regulated by ANVISA (Brazil)⁠[1], ARCSA (Ecuador)⁠[2], COFEPRIS (Mexico)⁠[3], ANMAT (Argentina)⁠[4], INVIMA (Colombia)⁠[5] and ISP (Chile)⁠[6]. How care is paid for in some of these countries: the SUS (Brazil)⁠[7]; public care and IESS (Ecuador)⁠[8]; IMSS, ISSSTE and IMSS-Bienestar (Mexico)⁠[9]; public care, obras sociales and prepaid plans (Argentina)⁠[10]; social health insurance (EPS) (Colombia)⁠[11]; and FONASA and ISAPREs (Chile)⁠[12].

[1] ANVISA. Checked 14 Nov 2026.

[2] ARCSA. Checked 14 Nov 2026.

[3] COFEPRIS. Checked 14 Nov 2026.

[4] ANMAT. Checked 19 Nov 2026.

[5] INVIMA. Checked 19 Nov 2026.

[6] Institute of Public Health of Chile (ISP). Checked 19 Nov 2026.

[7] CONITEC. Checked 14 Nov 2026.

[8] Ministry of Public Health of Ecuador. Checked 14 Nov 2026.

[9] Mexican Social Security Institute (IMSS). Checked 14 Nov 2026.

[10] Superintendence of Health Services (SSSalud). Checked 19 Nov 2026.

[11] Ministry of Health and Social Protection. Checked 19 Nov 2026.

[12] FONASA. Checked 19 Nov 2026.

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how polygenic Risk Scores products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Latin America.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Polygenic Risk Scores right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Polygenic Risk Scores in context

Free data on this topic

Quick answers

Frequently asked questions

How big is the Polygenic Risk Scores market in Latin America?
Placeholder estimate: about $10.6 Mn in 2025, rising to about $49.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Polygenic Risk Scores market in Latin America growing?
Placeholder estimate: about 18.8% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Polygenic Risk Scores market report cover?
The report splits the market by condition (Cardiovascular Disease, Cancer, Diabetes, Psychiatric Conditions) and user (Clinicians, Consumers, Researchers).
Who are the key players in the Polygenic Risk Scores market?
Key players include Genomics plc, Allelica, Myriad Genetics, Inc., 23andMe and Color Health.
What is driving the Polygenic Risk Scores market?
The falling cost of DNA sequencing, more targeted medicines, large national genome programmes and growing use of genetic results in everyday care are driving the polygenic Risk Scores market.
How much research is published on Polygenic Risk Scores?
PubMed lists 3,814 papers on Polygenic Risk Scores added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Back to Catalogue

Related Medical Devices reports in Latin America

See all

Related on genomics and diagnostics and lab testing

See the topic